WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-09 15:38:43
[post_modified_gmt] => 2024-08-09 19:38:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3450
[post_author] => 3
[post_date] => 2020-03-05 14:18:23
[post_date_gmt] => 2020-03-05 14:18:23
[post_content] => The Center for Biotechnology at Stony Brook University has announced the appointment of Dr. Mario R. Mendoza as Executive-In-Residence, and Dr. William Mann as its newest BioEntrepreneur-In-Residence (BEIR). Drs. Mendoza and Mann have extensive bioscience industry experience affording them unique perspectives in their respective roles in residence at the Center for Biotechnology (CFB). Each will work with the CFB and the Long Island Bioscience Hub (LIBH), a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health. Dr. Mann will identify commercially promising academic technologies that have the potential to support company formation while Dr. Mendoza will serve in an advisory capacity for bioscience startup companies in the hub.
Dr. Mario R Mendoza is a clinical anesthesiologist (practiced at the NIH) and currently a healthcare and pharmaceutical industry medical/medical affairs consultant with over 13 years of combined experience in patient clinical care, clinical development, R&D, medical affairs (Abbott, Pfizer and Centrexion Therapeutics), and FDA medical devices regulation. Dr. Mendoza earned his BS degree in chemistry from SUNY College at Old Westbury, and a MS in organic chemistry from the University of Illinois at Urbana-Champaign. He earned his M.D. from the University of Illinois at Chicago College of Medicine and then completed an FDA Commissioner’s Fellowship Program and stayed on at FDA as a Medical Officer/Medical Consultant.
Dr. William R. Mann is Principal of Lodestar Biopharma Solutions LLC, which assists clients in the development of R&D strategies for regulatory and commercial success, business development, and M&A. Previously, he was President and CEO at Helsinn Therapeutics (US), where he transformed the sixteen employee R&D start-up into a profitable commercial company with a team of over one hundred. At Sapphire Therapeutics, Dr. Mann facilitated an investor exit through M&A while managing the company’s lead clinical development program. He also held leadership positions at Novartis in R&D and business development. Dr. Mann holds a PhD in biochemistry from the University of Aberdeen, Scotland and an MBA from Rutgers University.
“We are excited to have Mario and Bill join us at the Center for Biotechnology. Their extensive and varied industry experiences are wonderful assets to our program. The further expansion of our BEIR Program allows us to continue to advance our agenda, fueling the developing bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said.
“I’m thrilled to become an Executive-in-Residence for the Center for Biotechnology.” stated Dr. Mendoza “I’m greatly looking forward to getting involved with biotech industry innovators collaborating with the organization. I believe the bioscience community in the region is robust and the support and partnership with organizations like the Center for Biotechnology are critical in driving innovation in the biotech space, and in getting innovative patient-centric products to market for the benefit of the patient and healthcare provider communities.”
“The work of the Center for Biotechnology is incredibly important to the bioscience community in the region, and I’m eager to be joining the organization.” Dr. Mann stated. “The innovation potential within the region is immense, and I look forward to the collaborative opportunities that lie ahead.”
Dr. Mann will work to identify a technology or technologies from within LIBH partner institutions that will create the foundation for licensing and company formation. He will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself for SBIR/STTR grant opportunities, as well as Angel and VC investment. In his role as Executive-in-Residence, Dr. Mendoza will offer invaluable support to the CFB client company portfolio by providing guidance and expertise in diverse areas including, but not limited to, product development, intellectual property strategy, regulatory affairs, capital formation, medical affairs and reimbursement.
The addition of Drs. Mendoza and Mann marks ten entrepreneurs and two executives-in-residence working with the Center for Biotechnology under their BIER program. Collectively, the Center for Biotechnology BEIRS have launched twelve new companies since the program’s inception in 2013.
View PDF announcement.
[post_title] => CFB Announces New Bioentrepreneur & Executive-In-Residence
[post_excerpt] => Joining the Center for Biotechnology as Dr. Mario R. Mendoza as Executive-In-Residence, and Dr. William Mann as BioEntrepreneur-In-Residence (BEIR).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-beir-2020
[to_ping] =>
[pinged] =>
[post_modified] => 2020-03-05 15:18:08
[post_modified_gmt] => 2020-03-05 15:18:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3450
[menu_order] => 74
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 3046
[post_author] => 3
[post_date] => 2018-08-22 20:10:08
[post_date_gmt] => 2018-08-22 20:10:08
[post_content] => Seasoned Industry Veterans Join Long Island Bioscience Hub’s BioEntrepreneur-in Residence Initiative
The Long Island Bioscience Hub, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, announced the appointment of Dr. Boris Shor and Mr. Peter Young as its newest BioEntrepreneurs-In-Residence (BEIRs). Dr. Shor and Mr. Young have extensive bioscience industry experience affording them unique perspectives in the role of Bio Entrepreneur-in-Residence. Each will work with the Center for Biotechnology to identify commercially promising academic technologies that have the potential to support company formation.
Dr. Shor has nearly 15 years of experience in leading oncology programs and external R&D partnerships at the large pharmas and biotech companies, with specific focus on preclinical development of small molecule kinase inhibitors and biologics. Previously at Pfizer, Dr. Shor led internal and external collaboration project teams to develop novel antibody-drug conjugates and supported BLA filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, he was a project team leader at the Oncology Unit of Wyeth, managing the discovery of novel kinase inhibitors for the treatment of cancer. He currently serves on the executive management team of early-stage biotech companies and is a founder of BioIDEA, a biotech pitch event in New York City. Dr. Shor received a Ph.D. in Molecular and Cell Biology at the State University of New York Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Pfizer.
Mr. Young is an experienced life science industry consultant with over thirty-five years experience and currently serves as an executive-in-residence with Pappas Capital, where he leads the firm’s initiatives in translational research. He also serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research and the Long Island Bioscience Hub External Review Board. He is a past member of the BIO board and chairman of NCBIO, the North Carolina industry trade association. Mr. Young earned a BA in History and an MBA from Indiana University.
“We couldn’t be more delighted to add Boris and Peter to the Center for Biotechnology’s roster of BioEntrepreneurs-in-Residence. The ongoing expansion of the BioEntrepreneur-in-Residence program is critical for the continued development of the bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said. “The attraction and retention of skilled bioscience management talent is an important component of ensuring companies can be launched and also grow here.”
“I am thrilled to join the Center for Biotechnology as a BioEntrepreneur-in-Residence” Dr. Shor stated, “and I have already begun the work of assessing technologies and building a company. I appreciate the resources the Center for Biotechnology offers through their many programs not only to me, but to emerging companies throughout New York.”
“Having worked with the Center for Biotechnology as an advisor for several years, I am pleased to formally join the Center as BioEntrepreneur-in-Residence” Peter Young stated. “There is an incredible amount of activity related to bioscience development currently taking place right now in the region, and the Center's many entrepreneurial programs provide a great springboard for significant industry expansion - I'm thrilled to be a part of it.”
In their roles as BEIRs, Dr. Shor and Mr. Young will work to identify a technology or technologies from within partner institutions that will create the foundation for licensing and company formation. They will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment.
Dr. Shor and Mr. Young join the eight BEIRs already working with the Center for Biotechnology who collectively have launched ten new companies in the last five years.
[post_title] => Long Island Bioscience Hub Appoints Additional BioEntrepreneurs-In-Residence
[post_excerpt] => Seasoned Industry Veterans Join Long Island Bioscience Hub’s BioEntrepreneur-in-Residence Initiative
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => libh-beir-2018
[to_ping] =>
[pinged] =>
[post_modified] => 2018-08-22 20:10:08
[post_modified_gmt] => 2018-08-22 20:10:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3046
[menu_order] => 114
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2913
[post_author] => 1
[post_date] => 2018-01-10 15:34:32
[post_date_gmt] => 2018-01-10 15:34:32
[post_content] => Celmatix, a next-generation women’s health company, has been awarded $4.5 million from Empire State Development’s New York City Regional Economic Development Council (REDC), to expand its headquarters in Manhattan.
Piraye Yurttas Beim, PhD, Founder and CEO of Celmatix stated “New York State has been there for Celmatix every step of the way as we’ve transitioned from ambitious startup to innovative next generation women’s health company. From the training I received through New York State’s Center for Biotechnology program at Stony Brook University, to the support we received from the Empire State Development START-UP New York program when it was time to build our first lab, and now, with this award as we prepare to take the next step in the evolution of our company, we are honored to have continued support to grow and thrive in New York.”
Additional Articles: pharmiweb
[post_title] => Celmatix awarded $4.5M to expand in NYS
[post_excerpt] => Celmatix receives $4.5 million to expand its headquarters in Manhattan.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => celmatix-awarded-4-5m-to-expand-in-nys
[to_ping] =>
[pinged] =>
[post_modified] => 2018-02-02 19:23:34
[post_modified_gmt] => 2018-02-02 19:23:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2913
[menu_order] => 128
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-09 15:38:43
[post_modified_gmt] => 2024-08-09 19:38:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 260
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
